Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

VCs Eye Europe's Drug Cabinet: Index, Orion Share Designs on Clinical Stage Compounds

This article was originally published in Start Up

Executive Summary

Two new investment vehicles have been formed to take advantage of the relative immaturity of Europe's life sciences industry. Index Ventures and Orion Health Care Equity Partners both see opportunities abound in Europe's biopharmaceutical start-ups, but they have different approaches.

You may also be interested in...



Spain's First Biotech VC

Signs are that Spanish biotech, until now held back by a lack of capital and management expertise, may be about to receive the kick-start it badly needs. Newly-created Ysios Capital Partners is the country's first specialist VC. It's raising a first fund worth €65 million ($92 million)--and it's not alone.

European IPOs Hold Their Own

The conventional wisdom is that European biopharma IPOs lag those in the US both in number and average size, held back by fragmented markets, stingy risk-averse investors, and a lack of specialists. The wisdom's changed (or some of it, anyway).

Pfizer's PowderMed Purchase Buoys VCs, Vaccines

Pfizer's October 2006 acquisition of DNA-vaccine specialist PowderMed was the largest ever acquisition of a UK biotech. PowderMed's investors saw a solid return on the deal, which underscored Big Pharma's rush to spread their bets on next-generation large-molecule platforms.

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

SC091543

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel